A Multicenter, Randomized, Patient, Investigator and Sponsor Blinded, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of CSJ148 in Pregnant Women With Primary HCMV Infection
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2018
At a glance
- Drugs CSJ 148 (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 23 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Jul 2018 Planned number of patients changed from 120 to 84.
- 03 Jul 2018 Planned End Date changed from 13 Oct 2022 to 15 Nov 2022.